多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪性肝炎合并2型糖尿病患者效果研究

doi:10.3969/j.issn.1672-5069.2016.02.012

摘要/Abstract

摘要： 目的探讨多烯磷脂酰胆碱联合维生素E对非酒精性脂肪性肝炎合并2型糖尿病患者的治疗效果。方法将83例非酒精性脂肪性肝炎合并2型糖尿病患者随机分为两组,其中实验组给予多烯磷脂酰胆碱和维生素E治疗,对照组则给予多烯磷脂酰胆碱治疗,两组总疗程均为8 w。通过随访观察,对两种方法的治疗效果进行比较分析。采用空腹抽取静脉血测定血糖;采用上海丰汇医学科技有限公司提供的试剂盒测定血脂;采用上海科华生物工程股份有限公司提供的试剂盒检测肝功能指标;使用西门子Sequoia512超声诊断仪进行肝脏检查,用来评估脂肪肝程度。结果实验组和对照组血糖水平都有所下降,其中实验组为7.6 mmol/L,对照组为7.8 mmol/L,两组间差异没有统计学意义（P>0.05）;治疗后实验组ALT和AST分别为（43.8±18.2） IU/L和（42.3±9.6） IU/L,均显著低于对照组[（59.0±10.8） IU/L和（51.5±12.2）IU/L,P<0.05];治疗后实验组甘油三脂和总胆固醇分别（1.50±0.57） mmol/L和（5.09±1.18） mmol/L,均显著低于对照组[（3.00±0.29） mmol/L和（5.78±1.23）mmol/L,P<0.05];治疗后实验组肝脏B超评分为（1.2±0.3）,显著低于对照组[（1.6±0.3）,P<0.05];实验组的总有效率为79.5%,显著高于对照组（54.5%,P<0.05）。结论多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪性肝炎合并2型糖尿病患者疗效优于单纯多烯磷脂酰胆碱治疗。

关键词: 酒精性脂肪性肝病, 2型糖尿病, 多烯磷脂酰胆碱, 维生素E

Abstract: Objective To explore the effect of polyene phosphatidylcholine combined with vitamin E in treatment of patients with nonalcoholic fatty liver disease and diabetes type 2. Methods Eighty three patients with nonalcoholic fatty liver disease and diabetes type 2 were randomly divided into two groups. Patients in the experimental group were given polyene phosphatidylcholine and vitamin E regularly for eight weeks,and patients in the control group received polyene phosphatidylcholine alone for eitht weeks. Then,the efficacy in the two groups as respect to normalization of blood biochemistry index and serum lipids were compared. ResultsAt the end of treatment,the blood glucose levels in experimental group and in the control group decreased,with a average of 7.6 mmol/L in patients of experimental group and 7.8 mmol/L in patients of the control group;Serum ALT and AST levels in experimental group were （43.8±18.2） IU/L and（42.3±9.6） IU/L,respectively,which were significantly lower than those in the controls[（59.0±10.8） IU/L and （51.5±12.2） IU/L,P<0.05];Blood TG and TC levels in experimental group were（1.50±0.57） mmol/L and （5.09±1.18） mmol/L,respectively,which were significantly lower than those in the controls[（3.00±0.29） mmol/L and（5.78±1.23） mmol/L,P<0.05];The B-mode ultrasound examination index of liver in the experimental group was（1.2±0.3）,significantly lower than that in the controls（1.6±0.3）;The effective rate in the experimental group was 79.5%,significantly higher than that in the controls（54.5%,P<0.05）. Conclusion Polyene phosphatidylcholine combined with vitamin E is more effective in the treatment of patients with nonalcoholic fatty liver disease and diabetes type 2 than polyene phosphatidylcholine alone.

Key words: Nonalcoholic fatty liver disease, Diabetes type 2, Polyene phosphatidylcholine, Vitamin E, Efficacy

肖丽萍, 余新沛, 刘岗, 钟武装, 蔡敏捷. 多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪性肝炎合并2型糖尿病患者效果研究[J]. 实用肝脏病杂志, 2016, 19(2): 172-174.

Xiao Liping, Yu Xinpei, Liu Gang. Research of polyene phosphatidylcholine combined with vitamin E in treatment of patients with nonalcoholic fatty liver disease and diabetes type 2[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 172-174.

参考文献

[1] 胡水清,张玫,牛小羽,等. 非酒精性脂肪性肝病的药物治疗进展. 现代生物医学进展,2014,11:2176-2179.
[2] 李春君,张秋梅,于德民,等. 2型糖尿病合并非酒精性脂肪肝的治疗. 药品评价,2011,8（7）:34-37.
[3] 齐婷,许樟荣. 2型糖尿病合并非酒精性脂肪性肝病的研究进展. 国际内分泌代谢杂志,2010,30（6）:398-400.
[4] Takeuchi Y,Ito H,Komatsu Y,et al. Non-alcoholic fatty liver disease is an independent predictor for macroangiopathy in Japanese type 2 diabetic patients:A cross-sectional study. Intern Med,2012,13:1667-1675.
[5] Leite NC,Salles GF,Araujo AL,et a1. Prevalence and associated factors of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Liver Int,2009,29:113-119.
[6] Targher G,Bertolini L,Padovani R,et a1. Prevalence of non alcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care,2007,30:1212-1218.
[7] 张秋梅,张喆,李金金. 初诊2型糖尿病患者脂肪肝患病率及相关因素分析. 天津医科大学学报,2007,23（2）:229-231.
[8] 中华医学会肝脏病学分会脂肪肝和酒精性肝病组. 非酒精性脂肪性肝病诊疗指南（2010年修订版）. 中华肝脏病杂志,2010,18（3）:163-166.
[9] 高鑫. 提高对非酒精性脂肪肝病的认识,早期防治代谢紊乱. 中华内分泌代谢杂志,2010,24（7）:529-530.
[10] Comar KM,Sterling RK. Drug therapy for nonalcoholic fatty liver disease. Aliment Pharmacol Ther,2006,23:207-215.
[11] 孙存序,郑宪玲,檀增桓,等. 多烯磷脂酰胆碱联合二甲双胍治疗2型糖尿病合并非酒精性脂肪性肝病的临床观察. 临床荟萃,2008,17:1272-1273.
[12] Hattori Y,Suzuki K,Hattori S,et al. Metformin inhibits cytokine-induced nuclear factor kappa B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension,2006,47:1183-1188.
[13] 张秀梅,胡长军,崔兆辉,等. 2型糖尿病并发非酒精性脂肪性肝病发病机制的研究进展. 现代生物医学进展,2013,8（7）:1389-1391.
[14] Cusi K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabet Obes,2009,16:141-149.
[15] 蓝苑元,雷宁,张晓菲,等. 续断提取物对非酒精性脂肪肝小鼠调脂保肝作用及其有效部位研究. 中草药,2011,12:2497-2501.
[16] Yokohama S,Yoneda M,Haneda M,et al. Herapeuticeicacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology,2004,40:1222-1225.
[17] Sanyal AJ,Chalasani N,Kowdley KV,et a1. Pioglitazone, vitamin E,or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,362:1675-1685.
[18] Merat S,Malekzadeh R,Sohrabi MR,et al. Probucol in the treatment of nonalcoholic steatohepatitis:an open-labeled study. J Clin Gastroenterol,2003,36: 266-268.
[19] 刘忠鑫,陈东风. 多烯磷脂酰胆碱联合还原型谷胱甘肽治疗非酒精性脂肪性肝炎87例临床研究. 当代医学,2012,9:19-20.
[20] 甘波. 多烯磷脂酰胆碱联合生活方式干预治疗非酒精性脂肪性肝炎临床观察. 中国社区医师,2015,5:14-15.
[21] 查月芳,刘芳,李力,等. 2型糖尿病合并非酒精性脂肪肝的临床特征及相关因素分析. 河北医药,2010,11:1369-1371.